We explore the reasons behind Pfizer’s decision to terminate the further development of lotiglipron, a weight loss drug. We explain how its stock reacted to the news and whether the corporation will continue to operate in the weight loss drug market. We also talk about other Pfizer medications that are currently in the registration stage.